Petr Jansa

Title: Petr Jansa: Innovator in Pyrimidine Compounds

Introduction

Petr Jansa is a notable inventor based in Lanskroun, Czech Republic. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on pyrimidine compounds. His research focuses on developing compounds that can inhibit the formation of nitric oxide and prostaglandin E2, which are crucial in various inflammatory and cancer diseases.

Latest Patents

Petr Jansa holds a patent for "Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof." This invention provides pyrimidine compounds of general formula (I), which effectively reduce the production of nitric oxide (NO) and prostaglandin E2 (PGE2) without negatively affecting cell viability. The compounds can decrease the production of these factors by up to 50% and are not cytotoxic. Additionally, the patent includes a method for preparing these pyrimidine compounds, a pharmaceutical composition comprising the substituted pyrimidine compounds, and their use in treating inflammatory and cancer diseases.

Career Highlights

Throughout his career, Petr Jansa has worked with esteemed institutions such as the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences and the Institute of Experimental Medicine of the Czech Academy of Sciences. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Petr Jansa has collaborated with notable colleagues, including Zlatko Janeba and Zdenek Zidek. These partnerships have enriched his research and fostered innovation in the field of medicinal chemistry.

Conclusion

Petr Jansa's contributions to the development of pyrimidine compounds represent a significant advancement in the treatment of inflammatory and cancer diseases. His innovative approach and dedication to research continue to impact the scientific community positively.